All In Biotech

Drug Trial Radar · NCT06347458

BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

Last checked: Nov 19, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 2024

Primary completion

Apr 2027

Study completion Aug 2027

Sponsor

Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, single-dose dose-escalation and dose-expansion study.

Conditions

  • Leukemia
  • Acute Myeloid Leukemia

Interventions

  • BG1805Biological

    A single infusion of BG1805 Injection administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1.Dose Limited Toxicity RateTime frame: Up to 28 days after BG1805 infusion.
  2. 2.Incidence of Treatment-Emergent Adverse EventsTime frame: Up to 24 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.